某医药公司产品组合优化内部的资料-.pptVIP

From Pipelines to PortfoliosAccommodating Richer Environment Managers want/need to know the entire distribution of reward; Managers want/need to optimize, in addition to evaluate portfolio; Managers need to relax assumptions used earlier, for example, Allow each approach in each indication to have unique probability of success Solution: A general model June 4-8, 2004 Choice Symposium * Choice Symposium May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * May 4-7, 2003 PMSA Annual Conference, Orlando FL * From Pipelines To Portfolios Min Ding Pennsylvania State University Jehoshua Eliashberg University of Pennsylvania Choice Symposium June 4-8, 2004 Outline Optimizing New Drug Pipeline – one business opportunity Ding and Eliashberg, 2002, Management Science From Pipelines to Portfolios – many business opportunities Some theoretical insights An empirical demonstration -- GlaxoSmithKline June 4-8, 2004 Choice Symposium * Terms Used in Presentation Indications Also known as disease Each indication is considered as one business opportunity e.g., AIDS We use the terms “pipeline or project” to represent the NPD structure for a given indication We use “approach” to represent a specific way (e.g., a compound, a biological molecule) of drug development tailored for a given indication. Therapeutical Classes Also known as therapeutical areas